| FDA cancer panel rejects Amgen drug |
Boston GlobeAP WASHINGTON - A panel of cancer specialists voted against a new use for Amgen's Xgeva in prostate cancer yesterday, saying the drug's ability to slow the spread of the disease did not translate into meaningful benefits for patients.
|
| 2012 Amgen Tour Route Information Now Available |
KMPH Fox 26By KMPH Web Staff - email The tour will make a stop in Clovis on May 16th. It will be the end of Stage 4, which starts in Sonora. Wednesday, Clovis Mayor Jose Flores and city council members met with organizers and the cycling community to provide the ...
|
| NPS Pharmaceuticals to Report 2011 Financial Results |
PharmiWeb.com (press release)NPS complements its proprietary programs with a royalty-based portfolio of products and product candidates that includes agreements with Amgen, GlaxoSmithKline, Kyowa Hakko Kirin, Nycomed, and Janssen Pharmaceuticals, Inc.
|
| The Contador Case |
PezCycling NewsPress Release: After intense planning and careful consideration, details for the 2012 Amgen Tour of California professional road cycling race have been announced. The 2012 edition of America's premier cycling race will feature new cities, ...
|
| Amgen, Inc. (AMGN) |
NASDAQAmgen, Inc. ( AMGN ) reported fourth quarter earnings per share of $1.19, 5 cents below the Zacks Consensus Estimate, but 3.5% above the year-ago period. However, Amgen provided better-than-expected guidance for 2012. The company expects earnings in ...
|
| Bull Of The Day: Amgen, Inc. (AMGN) |
Daily MarketsAmgen, Inc. (NASDAQ:AMGN) reported fourth quarter earnings per share of $1.19, 5 cents below the Zacks Consensus Estimate, but 3.5% above the year-ago period. However, Amgen provided better-than-expected guidance for 2012. The company expects earnings ...
|
| Amgen, Inc. (AMGN) |
InvestorIdeas.com (press release)Amgen, Inc. (AMGN) reported fourth quarter earnings per share of $1.19, 5 cents below the Zacks Consensus Estimate, but 3.5% above the year-ago period. However, Amgen provided better-than-expected guidance for 2012. The company expects earnings in the ...
|
